vs

Side-by-side financial comparison of Princeton Bancorp, Inc. (BPRN) and ImmunityBio, Inc. (IBRX). Click either name above to swap in a different company.

ImmunityBio, Inc. is the larger business by last-quarter revenue ($38.3M vs $20.7M, roughly 1.8× Princeton Bancorp, Inc.). Princeton Bancorp, Inc. runs the higher net margin — 29.3% vs -161.8%, a 191.1% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs 3.6%). Princeton Bancorp, Inc. produced more free cash flow last quarter ($20.6M vs $-71.3M).

Princeton Bancorp, Inc. is a U.S.-based bank holding company operating through its community banking subsidiary. It offers retail and commercial banking products including deposit accounts, small business loans, consumer loans, mortgages and wealth management services, primarily serving clients across New Jersey and the U.S. mid-Atlantic region.

ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.

BPRN vs IBRX — Head-to-Head

Bigger by revenue
IBRX
IBRX
1.8× larger
IBRX
$38.3M
$20.7M
BPRN
Growing faster (revenue YoY)
IBRX
IBRX
+403.4% gap
IBRX
407.0%
3.6%
BPRN
Higher net margin
BPRN
BPRN
191.1% more per $
BPRN
29.3%
-161.8%
IBRX
More free cash flow
BPRN
BPRN
$91.9M more FCF
BPRN
$20.6M
$-71.3M
IBRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
BPRN
BPRN
IBRX
IBRX
Revenue
$20.7M
$38.3M
Net Profit
$6.1M
$-61.9M
Gross Margin
99.0%
Operating Margin
38.2%
-169.0%
Net Margin
29.3%
-161.8%
Revenue YoY
3.6%
407.0%
Net Profit YoY
16.3%
-4.7%
EPS (diluted)
$0.89
$-0.06

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BPRN
BPRN
IBRX
IBRX
Q4 25
$20.7M
$38.3M
Q3 25
$21.5M
$32.1M
Q2 25
$21.1M
$26.4M
Q1 25
$20.9M
$16.5M
Q4 24
$20.0M
$7.6M
Q3 24
$19.2M
$6.1M
Q2 24
$18.1M
Q1 24
$17.4M
Net Profit
BPRN
BPRN
IBRX
IBRX
Q4 25
$6.1M
$-61.9M
Q3 25
$6.5M
$-67.3M
Q2 25
$688.0K
$-92.6M
Q1 25
$5.4M
$-129.6M
Q4 24
$5.2M
$-59.2M
Q3 24
$-4.5M
$-85.7M
Q2 24
$5.1M
Q1 24
$4.3M
Gross Margin
BPRN
BPRN
IBRX
IBRX
Q4 25
99.0%
Q3 25
99.4%
Q2 25
99.5%
Q1 25
99.6%
Q4 24
Q3 24
Q2 24
Q1 24
Operating Margin
BPRN
BPRN
IBRX
IBRX
Q4 25
38.2%
-169.0%
Q3 25
38.5%
-173.5%
Q2 25
2.8%
-269.8%
Q1 25
32.9%
-390.1%
Q4 24
34.0%
-919.0%
Q3 24
-29.1%
-1314.3%
Q2 24
34.1%
Q1 24
31.0%
Net Margin
BPRN
BPRN
IBRX
IBRX
Q4 25
29.3%
-161.8%
Q3 25
30.0%
-209.8%
Q2 25
3.3%
-350.3%
Q1 25
25.7%
-784.9%
Q4 24
26.1%
-783.4%
Q3 24
-23.3%
-1404.0%
Q2 24
28.4%
Q1 24
24.9%
EPS (diluted)
BPRN
BPRN
IBRX
IBRX
Q4 25
$0.89
$-0.06
Q3 25
$0.95
$-0.07
Q2 25
$0.10
$-0.10
Q1 25
$0.77
$-0.15
Q4 24
$0.75
$-0.08
Q3 24
$-0.68
$-0.14
Q2 24
$0.80
Q1 24
$0.68

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BPRN
BPRN
IBRX
IBRX
Cash + ST InvestmentsLiquidity on hand
$242.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$270.7M
$-500.5M
Total Assets
$2.3B
$501.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BPRN
BPRN
IBRX
IBRX
Q4 25
$242.8M
Q3 25
$257.8M
Q2 25
$153.7M
Q1 25
$61.6M
Q4 24
$149.8M
Q3 24
$130.4M
Q2 24
Q1 24
Total Debt
BPRN
BPRN
IBRX
IBRX
Q4 25
Q3 25
$0
Q2 25
$10.0M
Q1 25
Q4 24
$0
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BPRN
BPRN
IBRX
IBRX
Q4 25
$270.7M
$-500.5M
Q3 25
$266.6M
$-524.3M
Q2 25
$261.9M
$-570.7M
Q1 25
$267.0M
$-591.4M
Q4 24
$262.0M
$-489.1M
Q3 24
$261.5M
$-745.1M
Q2 24
$244.8M
Q1 24
$241.8M
Total Assets
BPRN
BPRN
IBRX
IBRX
Q4 25
$2.3B
$501.9M
Q3 25
$2.2B
$519.0M
Q2 25
$2.2B
$402.1M
Q1 25
$2.3B
$303.8M
Q4 24
$2.3B
$382.9M
Q3 24
$2.4B
$364.6M
Q2 24
$2.0B
Q1 24
$2.0B
Debt / Equity
BPRN
BPRN
IBRX
IBRX
Q4 25
Q3 25
0.00×
Q2 25
0.04×
Q1 25
Q4 24
0.00×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BPRN
BPRN
IBRX
IBRX
Operating Cash FlowLast quarter
$21.5M
$-70.4M
Free Cash FlowOCF − Capex
$20.6M
$-71.3M
FCF MarginFCF / Revenue
99.3%
-186.2%
Capex IntensityCapex / Revenue
4.3%
2.4%
Cash ConversionOCF / Net Profit
3.54×
TTM Free Cash FlowTrailing 4 quarters
$29.2M
$-308.8M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BPRN
BPRN
IBRX
IBRX
Q4 25
$21.5M
$-70.4M
Q3 25
$4.9M
$-68.9M
Q2 25
$3.1M
$-79.7M
Q1 25
$1.3M
$-85.9M
Q4 24
$14.7M
$-85.1M
Q3 24
$1.2M
$-98.8M
Q2 24
$4.3M
Q1 24
$4.8M
Free Cash Flow
BPRN
BPRN
IBRX
IBRX
Q4 25
$20.6M
$-71.3M
Q3 25
$4.7M
$-69.6M
Q2 25
$2.9M
$-80.8M
Q1 25
$1.1M
$-87.0M
Q4 24
$13.2M
$-87.3M
Q3 24
$766.0K
$-101.6M
Q2 24
$3.9M
Q1 24
$4.8M
FCF Margin
BPRN
BPRN
IBRX
IBRX
Q4 25
99.3%
-186.2%
Q3 25
21.6%
-217.2%
Q2 25
13.7%
-305.9%
Q1 25
5.0%
-526.9%
Q4 24
65.9%
-1155.4%
Q3 24
4.0%
-1663.2%
Q2 24
21.8%
Q1 24
27.3%
Capex Intensity
BPRN
BPRN
IBRX
IBRX
Q4 25
4.3%
2.4%
Q3 25
1.1%
2.3%
Q2 25
1.2%
4.1%
Q1 25
1.0%
6.8%
Q4 24
7.6%
28.0%
Q3 24
2.2%
45.7%
Q2 24
2.1%
Q1 24
0.4%
Cash Conversion
BPRN
BPRN
IBRX
IBRX
Q4 25
3.54×
Q3 25
0.76×
Q2 25
4.57×
Q1 25
0.23×
Q4 24
2.82×
Q3 24
Q2 24
0.84×
Q1 24
1.11×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons